CBIO vs RCUS vs AGEN vs EXEL vs IMVT vs JPM

For growth investors, Agenus Inc.

(AGEN) is the stronger pick with 10. 4% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Crescent Biopharma, Inc. (CBIO) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus Exelixis, Inc. at 19. 1x. On forward P/E, Agenus Inc. is actually cheaper at 4. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Exelixis, Inc. wins at 0. 29x versus JPMorgan Chase & Co. 's 0. 81x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +213. 0%, compared to -96. 8% for Agenus Inc. (AGEN). Over 10 years, the gap is even starker: EXEL returned +619. 9% versus CBIO's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exelixis, Inc.

(EXEL) is the lower-risk stock at 0. 81β versus Agenus Inc. 's 2. 26β — meaning AGEN is approximately 180% more volatile than EXEL relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agenus Inc.

(AGEN) is pulling ahead at 10. 4% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to -815. 0% for Crescent Biopharma, Inc.. Over a 3-year CAGR, CBIO leads at 424. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Exelixis, Inc.

(EXEL) is the more profitable company, earning 33. 7% net margin versus -1419. 6% for Crescent Biopharma, Inc. — meaning it keeps 33. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXEL leads at 37. 6% versus -1407. 5% for CBIO. At the gross margin level — before operating expenses — CBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Exelixis, Inc. (EXEL) is the more undervalued stock at a PEG of 0. 29x versus JPMorgan Chase & Co. 's 0. 81x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Agenus Inc. (AGEN) trades at 4. 2x forward P/E versus 15. 1x for Exelixis, Inc. — 10. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AGEN: 122. 1% to $7. 33.

In this comparison, JPM (1.

9% yield) pays a dividend. CBIO, RCUS, AGEN, EXEL, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Agenus Inc. (AGEN) carries a higher beta of 2. 26 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, AGEN: -95. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CBIO (Healthcare) and RCUS (Healthcare) and AGEN (Healthcare) and EXEL (Healthcare) and IMVT (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CBIO is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; AGEN is a small-cap quality compounder stock; EXEL is a mid-cap quality compounder stock; IMVT is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while CBIO, RCUS, AGEN, EXEL, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.